8-K: Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

Standard BioTools announces its financial results for Q4 and the full year 2024, highlighting revenue, cost reductions, and a strong balance sheet.

Summary

• Standard BioTools reported financial results for the fourth quarter and fiscal year ended December 31, 2024.
• Full year 2024 pro forma combined revenue was $175.1 million.
• The company achieved a 17% full year reduction in pro forma operating loss and a 33% year-over-year improvement in adjusted EBITDA.
• Operational cost reductions totaled an additional $10 million, reaching $90 million in synergies over 12 months.
• The company has a strong balance sheet with $295 million in cash, cash equivalents, restricted cash, and short-term investments, and no material debt at year end 2024.
• Standard BioTools expects to reach adjusted EBITDA positive in 2026.
• Revenue for fiscal year 2025 is expected to be in the range of $165 million to $175 million.
• Fourth quarter 2024 revenue was $46.7 million, a 9% decrease year-over-year.
• Full year 2024 revenue was $175.1 million, a 9% decrease year-over-year.
• The net loss for 2024 was $168.7 million, compared to a net loss of $164.3 million in 2023.
• Adjusted EBITDA for 2024 was a loss of $87.3 million, versus an adjusted EBITDA loss of $130.1 million in 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue declined, the company is focused on cost reductions, integration, and future growth opportunities. The strong balance sheet and anticipated EBITDA positivity in 2026 are positive indicators.

Positives

• The company achieved significant cost synergies, exceeding its initial target.
• The balance sheet is strong with a substantial cash position and no material debt.
• Adjusted EBITDA improved significantly year-over-year.
• Consumables revenue increased, indicating growth in key product areas.
• Non-GAAP operating expenses decreased, reflecting improved efficiency.
• The company expects to reach adjusted EBITDA positive in 2026.

Negatives

• Revenue decreased by 9% year-over-year for both the fourth quarter and full year 2024.
• Instrument revenue was down 25% in Q4 and 27% for the full year, impacted by capital constraints in end-markets.
• Services revenue decreased by 16% in Q4 and 17% for the full year.
• The company reported a net loss of $168.7 million for 2024.
• The company anticipates a decline in Americas academic revenue due to NIH funding pressures.

Risks

• The company faces risks related to the integration of acquisitions and the realization of expected synergies.
• There are risks associated with changes in the company's business or external market conditions.
• Anticipated NIH funding pressures could negatively impact revenue.
• The company is subject to risks related to developing, manufacturing, and selling new products.
• Interruptions or delays in the supply of components or materials could impact production.
• The company relies on sales of capital equipment, which can be subject to seasonal variations.
• Continued budgetary, inflationary, or recessionary pressures could impact performance.
• Uncertainties in contractual relationships and potential product performance issues pose risks.

Future Outlook

The company expects revenue in the range of $165 million to $175 million for fiscal year 2025 and anticipates reaching adjusted EBITDA positive in 2026.

Management Comments

• 2024 was a year of execution and integration despite a dynamic economic backdrop, said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools.
• We have streamlined our operations, unified our business systems and strengthened our management team, establishing a foundation for the next phase of growth.
• Powered by SBS, we came in at the top end of our 2024 revenue guidance, exceeded our original cost synergy target by $10 million, now running at $90 million in just twelve months.
• With integration efforts largely behind us, we have emerged as a more agile organization getting leaner and faster as we progress toward anticipated profitability in 2026.
• Looking ahead, in an uncertain environment our mission is clear execute with precision, drive continuous improvement and scale intelligently both organically and inorganically.
• We are shifting mix toward higher-margin offerings in attractive markets while unlocking the power of proteomics with our partner Illumina.
• We believe the imminent launch of our co-branded, NGS-based, distributed solution can transform the most exciting area of the market which is at least a billion-dollar opportunity.
• Success there will also allow us to continue to focus on taking advantage of an environment primed for consolidation.
• This next phase demands focus and relentless execution as we build a Standard BioTools for long-term growth and value creation.

Industry Context

The announcement highlights Standard BioTools' efforts to streamline operations and integrate the SomaLogic acquisition, reflecting a broader trend in the life sciences industry towards consolidation and efficiency improvements. The company's focus on higher-margin offerings and partnership with Illumina to unlock the power of proteomics aligns with the industry's increasing emphasis on advanced technologies and personalized medicine.

Comparison to Industry Standards

• While specific competitor data isn't provided, the company's focus on cost synergies and EBITDA improvement aligns with industry-wide efforts to enhance profitability.
• Companies like Danaher and Thermo Fisher Scientific also emphasize operational efficiency and strategic acquisitions to drive growth.
• Standard BioTools' partnership with Illumina in proteomics mirrors similar collaborations in the industry to leverage advanced technologies.
• The company's revenue outlook for 2025 suggests a cautious approach, considering potential NIH funding pressures, which is a common concern among life science companies reliant on government funding.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline but encouraged by the cost reduction efforts and future profitability targets.
• Employees may experience changes due to integration and restructuring activities.
• Customers may benefit from the company's focus on higher-margin offerings and advanced technologies.
• Suppliers may be impacted by the company's efforts to streamline operations and reduce costs.

Next Steps

• The company will host a conference call and webcast on February 26th, 2025, to discuss the fourth quarter and full year 2024 financial results.
• Standard BioTools will continue to execute with precision, drive continuous improvement, and scale intelligently both organically and inorganically.
• The company will focus on shifting mix toward higher-margin offerings in attractive markets while unlocking the power of proteomics with Illumina.
• Standard BioTools will focus on taking advantage of an environment primed for consolidation.

Key Dates